Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis

This publication has 15 references indexed in Scilit:

• Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish
  American Journal of Physiology-Heart and Circulatory Physiology, 2013
• Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS
  Journal of Chromatography B, 2013
• Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma
  Clinical Pharmacokinetics, 2012
• Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival
  Blood, 2012
• Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement
  Blood, 2010
• Cardiotoxicity of the Anticancer Therapeutic Agent Bortezomib
  The American Journal of Pathology, 2010
• Light-Chain (AL) Amyloidosis
  Clinical Journal of the American Society of Nephrology, 2006
• Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis
  Blood, 2006
• Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
  American Journal of Hematology, 2005
• Serum Cardiac Troponins and N-Terminal Pro-Brain Natriuretic Peptide: A Staging System for Primary Systemic Amyloidosis
  Journal of Clinical Oncology, 2004